Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24596954 | 0.74 | ALDH1A1 (0.44) | ALDH1A1ADRA2BPTGS1TDP1KDM4E | |
| SCHEMBL24899846 | 0.72 | ALOX5AP (0.34) | — | |
| SCHEMBL30780323 | 0.71 | MTOR (0.30) | — | |
| SCHEMBL30050566 | 0.70 | PIM1 (0.33) | KDM4ELMNAHTR2C | |
| SCHEMBL358326 | 0.70 | ALDH1A1 (0.52) | ALDH1A1ADRA2BPTGS1TDP1KDM4E | |
| SCHEMBL24782558 | 0.70 | NPC1 (0.39) | ALDH1A1MEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL9172166 | 0.68 | POLL (0.40) | ALDH1A1MEN1POLBKMT2ASMN1; SMN2 | |
| SCHEMBL9177763 | 0.68 | POLL (0.40) | ALDH1A1KDM4EMEN1KMT2AHTR2C | |
| Hydrochloric Acid SCHEMBL4332744 | 0.68 | ALDH1A1 (0.50) | ALDH1A1ADRA2BPTGS1TDP1KDM4E | |
| SCHEMBL28092534 | 0.67 | HTR2C (0.43) | ALDH1A1ADRA2BPTGS1TDP1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001898-A1 | Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof | ACCRO BIOSCIENCE HK LTD (HK) | 2026-01-01 | — | — | US | disclosed |
| EP-4551559-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF | Accro Bioscience (HK) Limited (HK) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024010963-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024010963-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001898-A1 | Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof | JAK1, JAK2, TYK2 | ALDH1A1 4319/4885ADRA2B 869/4885PTGS1 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.